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FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ): USE OF A TOOL TO AID DIAGNOSIS
To establish pertinent levels of FMQ (Fibromyalgia Moldofsky Questionnaire) score to guide a subject's further treatment, METHODS: The FMQ questionnaire, was administrated to a representative community sample of 1500 subjects in UK along with two validated questionnaires (LFESSQ London Fibromyalgia Epidemiology Study Screening Questionnaire and CES-D Center for Epidemiologic Studies Depression Scale) and a questionnaire assessing a decline in the restorative effects of sleep (SQA Sleep Quality Assessment). A descriptive analysis of the score was carried out using socio-demographic data (gender, age, type of town and socio-professional class) and the complaints reported by the subjects interviewed, RESULTS: The FMQ score was higher among women and those over 50 (5.0; 5.3). Women aged over 50 had an even higher FMQ score (5.5), which agreed with existing epidemiological data on fibromyalgia. There was no relationship between the FMQ score and geographic location, income, profession and sick leave prescribed by a doctor (regardless of length). The FMQ score was 3.0 in subjects who did not state any pain and 4.1 in those who did not respond positively on the LFESSQ. It increased to 8.7 among those who screened positive on the LFESSQ. The FMQ score varied between 9.7 and 10.4 in subjects who responded positively on the LFESSQ and who also experienced depressive symptoms, fatigue or a decline in the restorative effects of sleep. The FMQ score was 10.7 for subjects who screened positive on the LFESSQ and who also experienced fatigue and depressive symptoms, and increased to 11.3 when the four symptoms were experienced at once, CON-CLUSIONS: A FMQ score of less than 3 excludes a presumptive diagnosis of fibromyalgia syndrome and an FMQ score of above 8 should lead to specialist investigations. To validate the SQA (Sleep Quality Assessment) questionnaire which will help to identify subjects who with an unrestorative sleep, METHODS: The SQA questionnaire, was administered to a representative sample of 1500 subjects from the general UK population along with three questionnaires (FMQ: Fibromyalgia Moldofsky Questionnaire, LFESSQ London Fibromyalgia Epidemiology Study Screening Questionnaire, and CES-D Center for Epidemiologic Studies Depression Scale). The maximum score of 30 showed a large decline in the restorative effect of sleep. Internal consistency, structural and clinical validity were tested, RESULTS: Internal consistency was highly satisfactory (aCronbach > 0.8). The items making up each dimension were highly relevant to the dimension that they covered (R > 0.4) and no item presented a significant correlation (>0.8) with another item. Subjects responding positively on the LFESSQ had an SQA score that was significantly higher than subjects who responded negatively (14.6 vs 8.7). Similar differences were observed between subjects with and without probable depressive symptoms (15.4 vs 8.4) and a strong presumption of fibromyalgia syndrome (16.9 vs 8.0). The SQA score was 7.0 in subjects who did not report any pain and 7.1 in those who did not respond positively on the LFESSQ. It increased to 14.7 among those who screened positive on the LFESSQ. The CES-D score increased significantly with the SQA score. The SQA score was 16.7 [13.9-17.4] among subjects who screened positive on the LFESSQ and who either experienced fatigue or depressive symptoms or both, CONCLUSIONS: The restorative effect of sleep is reduced when the SQA score is greater or equal to 14 and good when the SQA score is less than 7. An SQA score of between 7 and 14 necessitates further examinations, which may include investigating physiological function during sleep.
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